Stockreport

New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

AKCEA THERAPEUTICS  (AKCA) 
Last akcea therapeutics earnings: 2/25 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.akceatx.com/media-investors/press-releases
PDF NEURO-TTR phase 3 open-label extension study showed TEGSEDI® (inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR am [Read more]